At a $692M market cap, ARVN screens like a distressed biotech with no earnings visibility and real solvency concerns. The absence of a P/E and Forward P/E, combined with EPS of -0.1 and EPS next year estimated at -$1.14, tells you profitability is not just absent—it’s deteriorating. The Altman Z-Score of -0.9 is a flashing distress signal, and a Piotroski F-Score of 2 confirms weak fundamental momentum. With ROIC at -21.90% and operating margin at -18.60%, this business is destroying capital, not compounding it. This is not a misunderstood growth story; it is a high-risk balance sheet situation priced at 2.9x sales where survival, not expansion, is the core question.